Trovagene, USC Norris Comprehensive Cancer Center Collaborate
Complete the form below to unlock access to ALL audio articles.
Trovagene, Inc. has announced that it has entered into a broad collaboration agreement with the USC Norris Comprehensive Cancer Center. This collaboration will seek to establish a standardized framework for the use of Trovera™ urine liquid biopsy testing at USC as well as to define practical considerations and best practices for liquid biopsy testing from urine. The collaboration will also explore the development of clinical treatment algorithms through investigational studies to solidify how and when liquid biopsy testing can be employed.
"The clinical data Trovagene has presented and published thus far illustrate the tremendous promise of using urinary ctDNA as a noninvasive sample type to detect and monitor clinically actionable oncogene mutations, and provide essential molecular information about a patient's disease," said Stephen B. Gruber, M.D., Ph.D., M.P.H., director of the USC Norris Comprehensive Cancer Center.
"One of our key goals is to advance personalized medicine by investigating leading edge technologies, and provide clarity to the field for how and when these emerging technologies should be used. Ultimately, this pioneering work will facilitate new standards in patient care, and pave the way for new cancer treatment guidelines."
Trovagene is engaged in numerous collaborations with leading cancer centers and academic institutions. These collaborations are designed to further delineate the clinical utility of its precision cancer monitoring technology and Trovera™ liquid biopsy tests for the evaluation of mutational status in patients with cancer, and the assessment of tumor dynamics in response to therapy.
"We look forward to working closely with clinicians and researchers at the USC Norris Comprehensive Cancer Center, a leader in cancer research, to further demonstrate the robustness and reliability of our technology in the identification of cancer mutations from urine," stated Mark Erlander, Ph.D., Chief Scientific Officer at Trovagene.
"Our collaboration is focused on conducting several novel studies that have potential to improve the standard-of-care for cancer treatment, and to accelerate adoption of our noninvasive tests into clinical practice."
